Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Hoxie

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Virus Evolution|January 18, 2020
Intragenic recombination influences rotavirus diversity and evolutionIrene Hoxie, John J Dennehy
Viruses|August 28, 2021
Rotavirus A Genome Segments Show Distinct Segregation and Codon Usage PatternsIrene Hoxie, John J Dennehy
Vaccine|August 28, 2025
Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in miceKirill Vasilev, Eduard Puente-Massaguer, Irene Hoxie, et al.
Frontiers in Immunology|June 25, 2024
Increased efficacy of influenza virus vaccine candidate through display of recombinant neuraminidase on virus like particlesLeticia Guzman Ruiz, Alexander M Zollner, Irene Hoxie, et al.
NPJ Vaccines|July 10, 2025
Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvantsKirill Vasilev, Irene Hoxie, Eduard Puente-Massaguer, et al.
Plos One|September 23, 2021
Protocol for safe, affordable, and reproducible isolation and quantitation of SARS-CoV-2 RNA from wastewaterMonica Trujillo, Kristen Cheung, Anna Gao, et al.
Vaccine|August 28, 2024
Enhancing NA immunogenicity through novel VLP designsLeticia Guzman Ruiz, Alexander M Zollner, Irene Hoxie, et al.
NPJ Vaccines|May 2, 2026
A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responsesIrene Hoxie, Kirill Vasilev, Jordan Clark, et al.
Vaccine|September 6, 2024
A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamstersIrene Hoxie, Kirill Vasilev, Jordan J Clark, et al.
Cell Reports|November 6, 2024
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccinationJordan J Clark, Irene Hoxie, Daniel C Adelsberg, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Virus Evolution|January 18, 2020
Intragenic recombination influences rotavirus diversity and evolutionIrene Hoxie, John J Dennehy
Viruses|August 28, 2021
Rotavirus A Genome Segments Show Distinct Segregation and Codon Usage PatternsIrene Hoxie, John J Dennehy
Vaccine|August 28, 2025
Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in miceKirill Vasilev, Eduard Puente-Massaguer, Irene Hoxie, et al.
Frontiers in Immunology|June 25, 2024
Increased efficacy of influenza virus vaccine candidate through display of recombinant neuraminidase on virus like particlesLeticia Guzman Ruiz, Alexander M Zollner, Irene Hoxie, et al.
NPJ Vaccines|July 10, 2025
Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvantsKirill Vasilev, Irene Hoxie, Eduard Puente-Massaguer, et al.
Plos One|September 23, 2021
Protocol for safe, affordable, and reproducible isolation and quantitation of SARS-CoV-2 RNA from wastewaterMonica Trujillo, Kristen Cheung, Anna Gao, et al.
Vaccine|August 28, 2024
Enhancing NA immunogenicity through novel VLP designsLeticia Guzman Ruiz, Alexander M Zollner, Irene Hoxie, et al.
NPJ Vaccines|May 2, 2026
A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responsesIrene Hoxie, Kirill Vasilev, Jordan Clark, et al.
Vaccine|September 6, 2024
A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamstersIrene Hoxie, Kirill Vasilev, Jordan J Clark, et al.
Cell Reports|November 6, 2024
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccinationJordan J Clark, Irene Hoxie, Daniel C Adelsberg, et al.
Pageof 2